Explanipedia

Increasing use of immunotherapy and prolonged survival among younger patients with primary CNS lymphoma: a population-based study Open

Magdalena Neuhauser, Thomas Roetzer-Pejrimovsky, Stefan Oberndorfer, Melitta Kitzwoegerer, Franz Payer , et al. · 2019

Background: Primary CNS lymphoma is a highly aggressive and rare type of extranodal non-Hodgkin lymphoma. Although, new therapeutic approaches have led to improved survival, the management of the disease poses a challenge, practice …

Increasing use of immunotherapy and prolonged survival among younger patients with primary CNS lymphoma: a population-based study Open

Magdalena Neuhauser, Thomas Roetzer-Pejrimovsky, Stefan Oberndorfer, Melitta Kitzwoegerer, Franz Payer , et al. · 2019

Background: Primary CNS lymphoma is a highly aggressive and rare type of extranodal non-Hodgkin lymphoma. Although, new therapeutic approaches have led to improved survival, the management of the disease poses a challenge, practice …

NIMG-12. CAN F-DOPA PET DIFFERENTIATE GLIOMA-RECURRENCE FROM TREATMENT-RELATED CHANGES? Open

Tadeja Urbanic Purkart, Franz Payer · 2017

In glioma therapy differentiating tumor progression from treatment related changes such as pseudoprogression and radionecrosis is crucial. However, there are no simple reliable tools to distinguish between such modalities. In unclear cases…

P02.01 ABTR-SANO Real-World Pattern of Care Study on Glioblastoma in the Austrian Population Open

Stefan Oberndorfer, Christine Marosi, Franz Payer, Martha Nowosielski, C. Floria , et al. · 2016

Glioblastoma is the most common malignant brain tumor in adults. Since 2005, state-of-the-art treatment consists of maximal safe resection followed by combined radio- and TMZ chemotherapy. AÂ number of population-based outcome and pattern …

P21.12 Germinoma mimicking a vanishing midbrain lesion on the MRI Open

Tadeja Urbanic Purkart, Etienne Holl, Thomas Seifert‐Held, Martin Asslaber, Franz Payer · 2016

NIMG-69THE IMPACT OF MRI PERFUSION IMAGING IN THE DIFFERENTIATION OF PROGRESSION AND PSEUDOPROGRESSION IN PATIENTS WITH GLIOBLASTOMA Open

Tadeja Urbanic Purkart, Franz Payer, Dennis Bohlsen, Franz Fazekas · 2015

ATCT-35QUALITY OF LIFE, COGNITIVE FUNCTION AND FUNCTIONAL STATUS IN THE EF-14 TRIAL: A PROSPECTIVE, MULTI-CENTER TRIAL OF TTFIELDS WITH TEMOZOLOMIDE COMPARED TO TEMOZOLOMIDE ALONE IN PATIENTS WITH NEWLY DIAGNOSED GBM Open

Jay‐Jiguang Zhu, Susan C. Pannullo, H. Maximilian Mehdorn, Franz Payer, Nicholas G. Avgeropoulos , et al. · 2015

BACKGROUND: Tumor Treating Fields (TTFields) are an anti-mitotic, electric-physical treatment modality. An interim analysis of the phase 3 trial comparing TTFields with maintenance temozolomide (TTFields/TMZ) showed superior progression fr…

Franz Payer YOU? Author Swipe